Generated $1.1 million in revenue from RenovoCath sales for the year ended December 31, 2025, a significant increase from $43,000 in 2024. 12 U.S. cancer centers are utilizing RenovoCath commercially, with 21 additional centers evaluating or preparing for activation, tripling the potential near-term commercial centers in the sales pipeline since Q1 2025. The Phase III TIGeR-PaC trial for IAG (intra-arterial delivery of gemcitabine via RenovoCath) in locally advanced pancreatic cancer (LAPC) is ongoing, with 104 patients randomized and 72 events occurred as of March 24, 2026. Enrollment for the TIGeR-PaC trial is anticipated to be completed by mid-2026, with final data expected in 2027. The first interim analysis (March 2023) of the TIGeR-PaC trial showed a 6-month median Overall Survival (OS) benefit (nearly a 60% improvement) and a greater than 65% reduction in adverse events for IAG versus the study control arm. The second interim analysis (Q2 2025) recommended continuation of the trial without modification, though the company elected to defer publishing the interim data to avoid compromising trial integrity. RenovoCath with gemcitabine (IAG) received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon New Drug Application (NDA) approval by the FDA. The initial target market for RenovoCath is estimated at approximately $400 million in peak annual U.S. sales, with potential expansion opportunities across other clinical indications creating a multi-billion-dollar total addressable market. The company incurred net losses of $11.2 million in 2025 and $8.8 million in 2024, with an accumulated deficit of $61.4 million as of December 31, 2025. An additional $10.0 million in gross proceeds was raised through a private placement offering completed in March 2026. Material weaknesses in internal control over financial reporting identified for 2025 and 2024 have been remediated as of December 31, 2025.